{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:57Z","timestamp":1761871077912,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.09.014","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T03:16:25Z","timestamp":1506136585000},"page":"879-883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Results of Upfront Therapy for Marginal Zone Lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Jos\u00e9 L.","family":"Ortega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noridza","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel","family":"Tirado-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deana","family":"Hallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wandaly I.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.09.014_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/asheducation.V2012.1.426.3798535","article-title":"The many faces of marginal zone lymphoma","volume":"2012","author":"Zinzani","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2017.09.014_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.V96.2.410.014k22_410_419","article-title":"The gastric marginal zone B-cell lymphoma of MALT type","volume":"96","author":"Zucca","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.014_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.6004\/jnccn.2006.0026","article-title":"Marginal zone lymphoma","volume":"4","author":"Shaye","year":"2006","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2017.09.014_bib4","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clml.2017.09.014_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC)","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.09.014_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.thj.6200013","article-title":"The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November, 1997","volume":"1","author":"Harris","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2017.09.014_bib8","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.09.014_bib9","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-1-4419-9019-8_23","article-title":"STATA: a statistical analysis system for examining biomedical data","volume":"537","author":"Boston","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clml.2017.09.014_bib11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan-Meier estimate","volume":"1","author":"Goel","year":"2010","journal-title":"Int J Ayurveda Res"},{"key":"10.1016\/j.clml.2017.09.014_bib12","doi-asserted-by":"crossref","first-page":"g5608","DOI":"10.1136\/bmj.g5608","article-title":"How to read a Kaplan-Meier survival plot","volume":"349","author":"Sedgwick","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2017.09.014_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2307\/2532208","article-title":"A\u00a0log-rank test for equivalence of two survivor functions","volume":"49","author":"Wellek","year":"1993","journal-title":"Biometrics"},{"key":"10.1016\/j.clml.2017.09.014_bib14","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib15","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/annonc\/mdg492","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)","volume":"14","author":"W\u00f6hrer","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib18","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","author":"Bennett","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2017.09.014_bib20","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1200\/JCO.2005.05.018","article-title":"State-of-the-art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.014_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017306328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017306328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:09Z","timestamp":1761870609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017306328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017306328"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of Upfront Therapy for Marginal Zone Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}